CPHA Canvax

Abstract

What is already known about this topic?

Mother-to-child transmission of hepatitis B virus (HBV), a leading cause of liver cancer, is targeted for global elimination.

What is added by this report?

During 2016–2020, global coverage with the third dose of hepatitis B vaccine remained between 82% and 85%, whereas timely coverage with hepatitis B birth dose increased from 37% to 43%. Coverage in 2020 was ≥90% for both the hepatitis B birth dose and the 3-dose series of hepatitis B vaccine in 41% of countries. In 11 countries, prevalence of HBV surface antigen among children was ≤0.1%.

What are the implications for public health practice?

Accelerating hepatitis B birth dose introduction, increasing coverage with the third dose of hepatitis B vaccine, and monitoring programmatic and impact indicators are essential for elimination of mother-to-child transmission of HBV.

Rating See Comments Ratings

Category:

Vaccine Preventable Diseases,Vaccine Preventable Disease Surveillance,Global Surveillance,Communicable Diseases,Hepatitis B Vaccine Preventable Diseases
Vaccine Preventable Disease Surveillance
Global Surveillance
Communicable Diseases
Hepatitis B

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.